troglitazone has been researched along with Coagulation Disorders, Blood in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Horikoshi, H | 1 |
| Hashimoto, T | 1 |
| Fujiwara, T | 1 |
1 review available for troglitazone and Coagulation Disorders, Blood
| Article | Year |
|---|---|
Troglitazone and emerging glitazones: new avenues for potential therapeutic benefits beyond glycemic control.
Topics: Animals; Arteriosclerosis; Blood Coagulation Disorders; Cardiac Output; Cholesterol; Chromans; Endot | 2000 |